Please use this identifier to cite or link to this item: http://ir.juit.ac.in:8080/jspui/jspui/handle/123456789/5760
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRazdan, Kumud-
dc.contributor.authorHanjura, Shivani [Guided by]-
dc.date.accessioned2022-08-12T09:20:29Z-
dc.date.available2022-08-12T09:20:29Z-
dc.date.issued2019-
dc.identifier.urihttp://ir.juit.ac.in:8080/jspui//xmlui/handle/123456789/5760-
dc.descriptionDual Degree-
dc.description.abstractThere are many biologics which are somewhat same but are not exact copy of the reference product. These are often called the bio-similar. Talking about this, these have higher atomic masses and are very complex and have been dictated in a completely different manner but global health management. These are produced from only the particulates present in the living cells. The recent proposition given by the United States Food and Drug Administration (FDA) recently gave a fascinating proposition in order to praise appurtenant care drug developed by Sandoz , and also, particularly, the demoralization of biosimilars. Early biologics have given in a lot of effort to be insignificantly useful in the the treatment of serious illnesses.en_US
dc.language.isoenen_US
dc.publisherJaypee University of Information Technology, Solan, H.P.en_US
dc.subjectBiologicsen_US
dc.subjectBioreactoren_US
dc.subjectBiosimilaren_US
dc.subjectAuto immune disordersen_US
dc.subjectEurope marketen_US
dc.titleComparison of Different Bio-similar for the Treatment of Auto-Immune Disorders in Europe Marketen_US
dc.typeProject Reporten_US
Appears in Collections:Dissertations (M.Tech.)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.